Mindfulness Awareness Practices for Insomnia for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Multiple Myeloma+1 MoreMindfulness Awareness Practices for Insomnia - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare a mindfulness-based insomnia treatment to sleep education in people undergoing stem cell transplants for multiple myeloma.

Eligible Conditions
  • Multiple Myeloma
  • Sleep

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 100 days after transplant procedure

Day 100
Number of Participants Completing Study Procedures
Up to 2 weeks
Number of Participants Enrolling in the Study

Trial Safety

Trial Design

2 Treatment Groups

Sleep Health Education
1 of 2
Mindfulness Awareness Practices for Insomnia
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Mindfulness Awareness Practices for Insomnia · No Placebo Group · N/A

Mindfulness Awareness Practices for Insomnia
Behavioral
Experimental Group · 1 Intervention: Mindfulness Awareness Practices for Insomnia · Intervention Types: Behavioral
Sleep Health Education
Behavioral
ActiveComparator Group · 1 Intervention: Sleep Health Information · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 100 days after transplant procedure

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
561 Previous Clinical Trials
1,153,232 Total Patients Enrolled
14 Trials studying Multiple Myeloma
1,189 Patients Enrolled for Multiple Myeloma
Jennifer Knight, MDPrincipal InvestigatorMedical College of Wisconsin
3 Previous Clinical Trials
85 Total Patients Enrolled
1 Trials studying Multiple Myeloma
25 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are eligible to receive melphalan 200 mg/m2 as conditioning regimen.
You are 18 years of age or older.
You must give voluntary written consent before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
You have been on systemic therapy for at least one year.
You are agreeable to random assignment and data collection, including survey completion and blood draws.